EC Number |
Inhibitors |
Structure |
---|
4.4.1.20 | KCl |
0.5 mM, about 25% inhibition |
|
4.4.1.20 | NaCl |
0.5 mM, about 25% inhibition |
|
4.4.1.20 | bovine serum albumin |
5 mg, 45% inhibition |
|
4.4.1.20 | aspirin |
blocks the STAT6-dependent interleukin-4-inducible expression of LTC4S |
|
4.4.1.20 | more |
cell treatment with ERK 1/2 specific inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) blocks LTC4S expression, pyrrolidine dithiocarbamate inhibits reactive oxygen species generation and NF-?B activation, which in turn blocks LTC4S expression |
|
4.4.1.20 | 5-[5-[(4-chlorophenyl)(cyclopropylmethyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid |
compound at 6 mg/kg body weight reduces LTE4 levels in peritoneal lavage fluid by 88%and significantly decreases vascular permeability in vivo. Potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells |
|
4.4.1.20 | leukotriene C4 |
end product inhibition |
|
4.4.1.20 | L-699,333 |
i.e. 2,[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]ethoxy]butanoic acid, reversible, competitive against glutathione and non-competitive against leukotriene A4 |
|
4.4.1.20 | 2-benzoyl-5-(5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl)benzoic acid |
i.e. TK04, competitive mode of binding versus leukotriene A4 |
|
4.4.1.20 | leukotriene C2 |
IC50: 0.0011 mM |
|